AR9.6 / Quest PharmaTech, University of Nebraska, OncoCare Therap - LARVOL DELTA

Evaluating Radiotheranostic Targets for Endometrial Cancer. (PubMed, J Nucl Med) - "Stochastic bioconjugation methods were used to append deferoxamine (DFO) to a trio of monoclonal antibodies: trastuzumab (αHER2), AR9.6 (αMUC16), and ATG-031 (αCD24). [89Zr]Zr-DFO-ATG-031 and [89Zr]Zr-DFO-trastuzumab exhibit significant promise for immuno-PET imaging of endometrial cancer. These probes may prove beneficial in the clinic, not only for the noninvasive staging and monitoring of the disease but also as companion imaging agents for HER2- and CD24-targeted therapeutics."

Journal • Cervical Cancer • Endometrial Cancer • Gynecologic Cancers • Gynecology • Oncology • Solid Tumor • CD24 • HER-2 • MUC16

Pretargeted alpha therapy in MUC16-positive high-grade serous ovarian cancer. (PubMed, Nucl Med Biol) - "We confirmed that pretargeting with AR9.6-TCO and [225Ac]Ac-mcp-PEG8-Tz has durable antitumor effects in high MUC16-expressing tumors. These findings demonstrate great potential for using pretargeting in combination with TAT for the treatment of ovarian cancer."

Journal • Hematological Disorders • High Grade Serous Ovarian Cancer • Oncology • Ovarian Cancer • Solid Tumor • MUC16

Structural Basis of MUC16 Recognition by Antibody AR9.6 (FOB-USA 2024) - No abstract available

Structural Basis for Multivalent MUC16 Recognition and Robust Anti-Pancreatic Cancer Activity of Humanized Antibody AR9.6. (PubMed, Mol Cancer Ther) - "The mechanism of action of huAR9.6 may depend on dense avid binding to homologous SEA domains on MUC16. The results of this study validate the translational therapeutic potential of huAR9.6 against MUC16-positive PDACs."

Journal • Gastrointestinal Cancer • Hepatology • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • MUC16